p53 in drug resistance in ovarian cancer

被引：27

作者：

Lavarino, C

Delia, D

DiPalma, S

Zunino, F

Pilotti, S

机构：

[1] IST NAZL STUDIO & CURA TUMORI,DEPT ANAT PATHOL & CYTOPATHOL,I-20133 MILAN,ITALY

[2] IST NAZL STUDIO & CURA TUMORI,DEPT EXPT ONCOL A,I-20133 MILAN,ITALY

[3] IST NAZL STUDIO & CURA TUMORI,DEPT EXPT ONCOL A,I-20133 MILAN,ITALY

[4] IST NAZL STUDIO & CURA TUMORI,DEPT EXPT ONCOL B,I-20133 MILAN,ITALY

来源：

LANCET | 1997年 / 349卷 / 9064期

关键词：

D O I：

10.1016/S0140-6736(05)62140-X

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1556 / 1556

页数：1

共 5 条

[1]

Debernardis D, 1997, CANCER RES, V57, P870

[2] p53 activity and chemotherapy [J].

Delia, D ;

Mizutani, S ;

Lamorte, G ;

Goi, K ;

Iwata, S ;

Pierotti, MA .

NATURE MEDICINE, 1996, 2 (07) :724-725

[3]

RIGHETTI SC, 1996, CANCER RES, V56, P639

[4] Role of p53 in drug resistance in ovarian cancer [J].

Shelling, AN .

LANCET, 1997, 349 (9054) :744-745

[5] Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis [J].

Wahl, AF ;

Donaldson, KL ;

Fairchild, C ;

Lee, FYF ;

Foster, SA ;

Demers, GW ;

Galloway, DA .

NATURE MEDICINE, 1996, 2 (01) :72-79

← 1 →